TY - JOUR
T1 - Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location
AU - Karremann, Michael
AU - Gielen, Gerrit H
AU - Hoffmann, Marion
AU - Wiese, Maria
AU - Colditz, Niclas
AU - Warmuth-Metz, Monika
AU - Bison, Brigitte
AU - Claviez, Alexander
AU - van Vuurden, Dannis G
AU - von Bueren, André O
AU - Gessi, Marco
AU - Kühnle, Ingrid
AU - Hans, Volkmar H
AU - Benesch, Martin
AU - Sturm, Dominik
AU - Kortmann, Rolf-Dieter
AU - Waha, Andreas
AU - Pietsch, Torsten
AU - Kramm, Christof M
N1 - © The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected]
PY - 2018/1/10
Y1 - 2018/1/10
N2 - Background: The novel entity of "diffuse midline glioma, H3 K27M-mutant" has been defined in the 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system (CNS). Tumors of this entity arise in CNS midline structures of predominantly pediatric patients and are associated with an overall dismal prognosis. They are defined by K27M mutations in H3F3A or HIST1H3B/C, encoding for histone 3 variants H3.3 and H3.1, respectively, which are considered hallmark events driving gliomagenesis.Methods: Here, we characterized 85 centrally reviewed diffuse gliomas on midline locations enrolled in the nationwide pediatric German HIT-HGG registry regarding tumor site, histone 3 mutational status, WHO grade, age, sex, and extent of tumor resection.Results: We found 56 H3.3 K27M-mutant tumors (66%), 6 H3.1 K27M-mutant tumors (7%), and 23 H3-wildtype tumors (27%). H3 K27M-mutant gliomas shared an aggressive clinical course independent of their anatomic location. Multivariate regression analysis confirmed the significant impact of the H3 K27M mutation as the only independent parameter predictive of overall survival (P = 0.009). In H3 K27M-mutant tumors, neither anatomic midline location nor histopathological grading nor extent of tumor resection had an influence on survival.Conclusion: These results substantiate the clinical significance of considering diffuse midline glioma, H3 K27M-mutant, as a distinct entity corresponding to WHO grade IV, carrying a universally fatal prognosis.
AB - Background: The novel entity of "diffuse midline glioma, H3 K27M-mutant" has been defined in the 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system (CNS). Tumors of this entity arise in CNS midline structures of predominantly pediatric patients and are associated with an overall dismal prognosis. They are defined by K27M mutations in H3F3A or HIST1H3B/C, encoding for histone 3 variants H3.3 and H3.1, respectively, which are considered hallmark events driving gliomagenesis.Methods: Here, we characterized 85 centrally reviewed diffuse gliomas on midline locations enrolled in the nationwide pediatric German HIT-HGG registry regarding tumor site, histone 3 mutational status, WHO grade, age, sex, and extent of tumor resection.Results: We found 56 H3.3 K27M-mutant tumors (66%), 6 H3.1 K27M-mutant tumors (7%), and 23 H3-wildtype tumors (27%). H3 K27M-mutant gliomas shared an aggressive clinical course independent of their anatomic location. Multivariate regression analysis confirmed the significant impact of the H3 K27M mutation as the only independent parameter predictive of overall survival (P = 0.009). In H3 K27M-mutant tumors, neither anatomic midline location nor histopathological grading nor extent of tumor resection had an influence on survival.Conclusion: These results substantiate the clinical significance of considering diffuse midline glioma, H3 K27M-mutant, as a distinct entity corresponding to WHO grade IV, carrying a universally fatal prognosis.
KW - Adolescent
KW - Brain Neoplasms/diagnosis
KW - Child
KW - Female
KW - Glioma/diagnosis
KW - Histones/genetics
KW - Humans
KW - Male
KW - Mutation/genetics
KW - Neoplasm Grading
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85040932931&partnerID=8YFLogxK
U2 - 10.1093/neuonc/nox149
DO - 10.1093/neuonc/nox149
M3 - Article
C2 - 29016894
SN - 1522-8517
VL - 20
SP - 123
EP - 131
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - 1
ER -